At a glance
ClinicalIndex Comparison RecordN/ACompleted· 605 enrolled
Drug / intervention
no intervention +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-tnf Inhibitor Antibody-mediated Blockade Of Drug Efficacy In Rheumatoid Arthritis (Antibody-ra)
In Brief
An observational study evaluating no intervention for Rheumatoid Arthritis. Completed, enrolled 605 participants across 54 sites in 5 countries.
Detailed Summary
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Australia, Bulgaria, Turkey (Türkiye), United States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartJan 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedNov 11, 2013
Enrollment StartJan 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.6 years ago
Interventions
no interventionother
no interventionother
no interventionother